Research progress on eosinophilic asthma

doi:10.19983/j.issn.2096-8493.20220073

Abstract

Abstract:

Asthma is a heterogenous chronic airway inflammatory disease with various phenotypes,among which eosinophilic asthma (EA) is the most common one. Persistent eosinophilic airway inflammation may lead to severe asthma, and thus accounts for the high morbidity and mortality rates. Allergic EA and non-allergic EA subtypes varied significantly in terms of their clinical characteristics and pathogenesis. Recognizing pathogenic mechanism of EA is of great significance for disease management and for improving patient’s prognosis. In this review, we summarized the research progress on EA.

Key words: Eosinophils, Asthma, Disease attributes, Pathogenic mechanism, Diagnosis

CLC Number:

R562.2+5

Lin Huimin, Fu Yu, Fang Zhangfu, Xie Jiaxing. Research progress on eosinophilic asthma[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(4): 328-333. doi: 10.19983/j.issn.2096-8493.20220073

Figures/Tables 2

References 50

[1]	GBD 2015 Chronic Respiratory Disease Collaborators Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, 5 (9): 691-706. doi: 10.1016/S2213-2600(17)30293-X. doi: 10.1016/S2213-2600(17)30293-X URL
[2]	Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest, 2021, 160 (3): 814-830. doi: 10.1016/j.chest.2021.04.013. doi: 10.1016/j.chest.2021.04.013 pmid: 33887242
[3]	de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res, 2015, 1 (1): 00024-2015. doi: 10.1183/23120541.00024-2015. doi: 10.1183/23120541.00024-2015
[4]	Hammad H, Lambrecht BN. The basic immunology of asthma. Cell, 2021, 184(9): 2521-2522. doi: 10.1016/j.cell.2021.04.019. doi: 10.1016/j.cell.2021.04.019 URL
[5]	Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol, 2019, 144 (1): 1-12. doi: 10.1016/j.jaci.2019.05.031. doi: 10.1016/j.jaci.2019.05.031 URL
[6]	Van Hulst G, Bureau F, Desmet CJ. Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity? Int J Mol Sci, 2021, 22 (18): 10150. doi: 10.3390/ijms221810150. doi: 10.3390/ijms221810150 URL
[7]	Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol, 2015, 16(1): 45-56. doi: 10.1038/ni.3049. doi: 10.1038/ni.3049 pmid: 25521684
[8]	Bohrer AC, Castro E, Hu Z, et al. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J Exp Med, 2021, 218 (10): e20210469. doi: 10.1084/jem.20210469. doi: 10.1084/jem.20210469
[9]	Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol, 2017, 17(12): 746-760. doi: 10.1038/nri.2017.95. doi: 10.1038/nri.2017.95 pmid: 28891557
[10]	Shah K, Ignacio A, McCoy KD, et al. The emerging roles of eosinophils in mucosal homeostasis. Mucosal Immunol, 2020, 13(4): 574-583. doi: 10.1038/s41385-020-0281-y. doi: 10.1038/s41385-020-0281-y URL
[11]	Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest, 2016, 126 (9): 3279-3295. doi: 10.1172/JCI85664. doi: 10.1172/JCI85664 URL
[12]	Van Hulst G, Batugedara HM, Jorssen J, et al. Eosinophil diversity in asthma. Biochem Pharmacol, 2020, 179: 113963. doi: 10.1016/j.bcp.2020.113963. doi: 10.1016/j.bcp.2020.113963 URL
[13]	Wechsler ME, Munitz A, Ackerman SJ, et al. Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clin Proc, 2021, 96 (10): 2694-2707. doi: 10.1016/j.mayocp.2021.04.025. doi: 10.1016/j.mayocp.2021.04.025 pmid: 34538424
[14]	Granger V, Zerimech F, Arab J, et al. Blood eosinophil cationic protein and eosinophil-derived neurotoxin are associated with different asthma expression and evolution in adults. Thorax, 2022, 77(6): 552-562. doi: 10.1136/thoraxjnl-2021-217343. doi: 10.1136/thoraxjnl-2021-217343 URL
[15]	Choi Y, Le Pham D, Lee DH, et al. Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma. Exp Mol Med, 2018, 50 (8): 1-8. doi: 10.1038/s12276-018-0136-8. doi: 10.1038/s12276-018-0136-8
[16]	Ueki S, Konno Y, Takeda M, et al. Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. J Allergy Clin Immunol, 2016, 137 (1): 258-267. doi: 10.1016/j.jaci.2015.04.041. doi: 10.1016/j.jaci.2015.04.041 URL
[17]	Lu Y, Huang Y, Li J, et al. Eosinophil extracellular traps drive asthma progression through neuro-immune signals. Nat Cell Biol, 2021, 23 (10): 1060-1072. doi: 10.1038/s41556-021-00762-2. doi: 10.1038/s41556-021-00762-2 URL
[18]	Grozdanovic MM, Doyle CB, Liu L, et al. Charcot-Leyden crystal protein/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis. J Allergy Clin Immunol, 2020, 146 (2): 377-389.e10. doi: 10.1016/j.jaci.2020.01.013. doi: S0091-6749(20)30100-7 pmid: 31982451
[19]	Persson EK, Verstraete K, Heyndrickx I, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science, 2019, 364 (6442): eaaw4295. doi: 10.1126/science.aaw4295. doi: 10.1126/science.aaw4295
[20]	Mack EA, Pear WS. Transcription factor and cytokine regulation of eosinophil lineage commitment. Curr Opin Hematol, 2020, 27 (1): 27-33. doi: 10.1097/MOH.0000000000000552. doi: 10.1097/MOH.0000000000000552 URL
[21]	Zustakova M, Kratochvilova L, Slama P. Apoptosis of Eosino-phil Granulocytes. Biology (Basel), 2020, 9 (12): 457. doi: 10.3390/biology9120457. doi: 10.3390/biology9120457
[22]	Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine, 2015, 75 (1): 68-78. doi: 10.1016/j.cyto.2015.05.014. doi: 10.1016/j.cyto.2015.05.014 URL
[23]	Godar M, Deswarte K, Vergote K, et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol, 2018, 142 (4): 1185-1193. e4. doi: 10.1016/j.jaci.2018.06.002. doi: 10.1016/j.jaci.2018.06.002 URL
[24]	Gowthaman U, Chen JS, Zhang B, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science, 2019, 365 (6456): eaaw6433. doi: 10.1126/science.aaw6433. doi: 10.1126/science.aaw6433
[25]	Sugita K, Steer CA, Martinez-Gonzalez I, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol, 2018, 141 (1): 300-310.e11. doi: 10.1016/j.jaci.2017.02.038. doi: 10.1016/j.jaci.2017.02.038 URL
[26]	Wang W, Li Y, Lv Z, et al. Bronchial Allergen Challenge of Patients with Atopic Asthma Triggers an Alarmin (IL-33, TSLP, and IL-25) Response in the Airways Epithelium and Submucosa. J Immunol, 2018, 201 (8): 2221-2231. doi: 10.4049/jimmunol.1800709. doi: 10.4049/jimmunol.1800709 pmid: 30185520
[27]	李赞华. 白细胞介素25与33在支气管哮喘发生中的作用. 结核病与肺部健康杂志, 2017, 6 (2): 190-192. doi: 10.3969/j.issn.2095-3755.2017.02.024. doi: 10.3969/j.issn.2095-3755.2017.02.024
[28]	Machida K, Aw M, Salter BMA, et al. The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lym-phoid Cells in Subjects with Eosinophilic Asthma. Am J Respir Crit Care Med, 2020, 202 (8): 1105-1114. doi: 10.1164/rccm.201909-1722OC. doi: 10.1164/rccm.201909-1722OC URL
[29]	Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med, 2013, 19 (8): 977-979. doi: 10.1038/nm.3300. doi: 10.1038/nm.3300 pmid: 23921745
[30]	Brandt EB, Bolcas PE, Ruff BP, et al. IL33 contributes to diesel pollution-mediated increase in experimental asthma severity. Allergy, 2020, 75 (9): 2254-2266. doi: 10.1111/all.14181. doi: 10.1111/all.14181 pmid: 31922608
[31]	Brandt EB, Bolcas PE, Ruff BP, et al. TSLP contributes to allergic airway inflammation induced by diesel exhaust particle exposure in an experimental model of severe asthma. Clin Exp Allergy, 2020, 50(1):121-124. doi: 10.1111/cea.13512. doi: 10.1111/cea.13512 pmid: 31610053
[32]	Michaudel C, Mackowiak C, Maillet I, et al. Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33 J Allergy Clin Immunol, 2018, 142(3): 942-958. doi: 10.1016/j.jaci.2017.11.044. doi: S0091-6749(18)30028-9 pmid: 29331644
[33]	Hiraishi Y, Yamaguchi S, Yoshizaki T, et al. IL-33, IL-25 and TSLP contribute to development of fungal-associated protease-induced innate-type airway inflammation. Sci Rep, 2018, 8 (1): 18052. doi: 10.1038/s41598-018-36440-x. doi: 10.1038/s41598-018-36440-x URL
[34]	Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest, 2019, 129(4): 1441-1451. doi: 10.1172/JCI124606. doi: 10.1172/JCI124606 URL
[35]	Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. Chest, 2019, 156 (1): 141-149. doi: 10.1016/j.chest.2019.04.101. doi: 10.1016/j.chest.2019.04.101 URL
[36]	Lee HS, Park DE, Lee JW, et al. Role of interleukin-23 in the development of nonallergic eosinophilic inflammation in a murine model of asthma. Exp Mol Med, 2020, 52(1): 92-104. doi: 10.1038/s12276-019-0361-9. doi: 10.1038/s12276-019-0361-9 URL
[37]	Wangberg H, White AA. Aspirin-exacerbated respiratory disease. Curr Opin Immunol, 2020, 66: 9-13. doi: 10.1016/j.coi.2020.02.006. doi: S0952-7915(20)30022-4 pmid: 32299015
[38]	Li KL, Lee AY, Abuzeid WM. Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and ManagementMed Sci (Basel), 2019, 7(3): 45. doi: 10.3390/medsci7030045. doi: 10.3390/medsci7030045
[39]	Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J, 2021, 59 (1): 2102730. doi: 10.1183/13993003.02730-2021. doi: 10.1183/13993003.02730-2021 URL
[40]	Bakakos A, Loukides S, Bakakos P. Severe Eosinophilic Asthma. J Clin Med, 2019, 8(9): 1375. doi: 10.3390/jcm8091375. doi: 10.3390/jcm8091375 URL
[41]	Burgess JK, Jonker MR, Berg M, et al.Periostin: contributor to abnormal airway epithelial function in asthma? Eur Respir J, 2021, 57 (2): 2001286. doi: 10.1183/13993003.01286-2020. doi: 10.1183/13993003.01286-2020 URL
[42]	Chen M, Shepard K 2nd, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy, 2021, 51 (4): 546-555. doi: 10.1111/cea.13790. doi: 10.1111/cea.13790 URL
[43]	de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res, 2016, 2 (2): 00100-2015. doi: 10.1183/23120541.00100-2015. doi: 10.1183/23120541.00100-2015
[44]	Bousquet J, Humbert M, Gibson PG, et al. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. J Allergy Clin Immunol Pract, 2021, 9 (7): 2702-2714. doi: 10.1016/j.jaip.2021.01.011. doi: 10.1016/j.jaip.2021.01.011 URL
[45]	Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J, 2018, 51 (5):1702523. doi: 10.1183/13993003.02523-2017. doi: 10.1183/13993003.02523-2017
[46]	Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med, 2019, 7 (1): 46-59. doi: 10.1016/S2213-2600(18)30406-5. doi: 10.1016/S2213-2600(18)30406-5 URL
[47]	Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy, 2020, 75 (5): 1058-1068. doi: 10.1111/all.14268. doi: 10.1111/all.14268 pmid: 32154939
[48]	Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines-recommendations on the use of biologicals in severe asthma. Allergy, 2020, 75 (5): 1023-1042. doi: 10.1111/all.14221. doi: 10.1111/all.14221 pmid: 32034960
[49]	Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med, 2017, 377 (10): 936-946. doi: 10.1056/NEJMoa1704064. doi: 10.1056/NEJMoa1704064 URL
[50]	Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med, 2021, 384 (19): 1800-1809. doi: 10.1056/NEJMoa2034975. doi: 10.1056/NEJMoa2034975 URL

临床指标	变应性EA	非变应性EA
诱因	变应原(多为吸入变应原)	非过敏因素(PM2.5、臭氧及微生物等)
发病年龄	多为早发性(儿童)	多为迟发性(成人)
疾病发展进程	进展相对缓慢	起病症状重,进展速度快
伴发疾病	常伴其他变应性疾病(变应性皮炎、变应性鼻炎等)	慢性鼻炎-鼻窦炎伴或不伴鼻息肉
过敏史	多为过敏体质,有食物药物过敏史或吸入性、接触性过敏史	多无
预后	规律使用抗炎药物能较好控制	难控制,容易发生激素抵抗,或进展为重症
外周血总IgE	升高	多数为正常水平